ReviewTrends in molecular medicine2020
Activity-Based Diagnostics: An Emerging Paradigm for Disease Detection and Monitoring.
Review in Trends in molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 93 citations in OpenAlex.
- Multimodal profiling of pro-inflammatory protease activity identifies caspase-1 as a target for lung cancer interception.Science advances · 2026Article
- Chemical basis of fluorogenic substrate probe design: revisiting the past to discover the new in biochemistry.RSC chemical biology · 2026Review
- Multicyclic D-Stereospecific Hydrolase Dimer With High Sustained Activity.Angewandte Chemie (International ed. in English) · 2026Article
- Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors.Nature chemical biology · 2026Article
- Matrix Metalloproteinase‑9 (MMP-9) Activatable Gold Nanoparticles forACS applied nano materials · 2026Article
- Article
- Deep learning guided design of protease substrates.Nature communications · 2026Article
- Clinical relevance of extracellular vesicles in cancer - therapeutic and diagnostic potential.Nature reviews. Clinical oncology · 2025Review
- Artificially Engineered Synthetic Biomarkers Revolutionizing Early Diagnosis of Diseases.Molecules (Basel, Switzerland) · 2025Review
- Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis.Science advances · 2025Article
- Development of Single-Molecule Enzyme Activity Assay for Serine Hydrolases Using Activity-Based Protein Labeling Probes.Small methods · 2025Article
- Single-Molecule Enzyme Activity Analysis for Illuminating Pathological Proteoforms.ACS central science · 2025Review
- Conformationally Locked Peptide-DNA Nanostructures for CRISPR-Amplified Activity-Based Sensing.Angewandte Chemie (International ed. in English) · 2025Article
- Enzyme Catalysis for Sustainable Value Creation Using Renewable Biobased Resources.Molecules (Basel, Switzerland) · 2024Review
- Synthetic Protein-to-DNA Input Exchange for Protease Activity Detection Using CRISPR-Cas12a.Analytical chemistry · 2024Article
- A breath-based in vitro diagnostic assay for the detection of lower respiratory tract infections.PNAS nexus · 2024Article
- Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Thioester-Based Coupled Fluorogenic Assays in Microdevice for the Detection of Single-Molecule Enzyme Activities of Esterases with Specified Substrate Recognition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Experimental In Vitro Microfluidic Calorimetric Chip Data towards the Early Detection of Infection on Implant Surfaces.Sensors (Basel, Switzerland) · 2024Article
- Identification of activity-based biomarkers for early-stage pancreatic tumors in blood using single-molecule enzyme activity screening.Cell reports methods · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Diagnostics to accurately detect disease and monitor therapeutic response are essential for effective clinical management. Bioengineering, chemical biology, molecular biology, and computer science tools are converging to guide the design of diagnostics that leverage enzymatic activity to measure or produce biomarkers of disease. We review recent advances in the development of these 'activity-based diagnostics' (ABDx) and their application in infectious and noncommunicable diseases. We highlight efforts towards both molecular probes that respond to disease-specific catalytic activity to produce a diagnostic readout, as well as diagnostics that use enzymes as an engineered component of their sense-and-respond cascade. These technologies exemplify how integrating techniques from multiple disciplines with preclinical validation has enabled ABDx that may realize the goals of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.